Incorporation Year: -
No. of Employees: -

- - -

Website: www.exelixis.com

About the company:


06/12/12 14:16:55FDA Approves COMETRIQ™ for Treatment of Progressive, Metastatic Medullary Thyroid Cancer
01/10/12 14:02:55Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012
11/09/12 12:15:15Exelixis Provides Update on ODAC Panel for Cabozantinib
23/08/12 14:37:47Exelixis Announces Pricing of Concurrent Offerings of 30 Million Shares of Common Stock
31/07/12 07:27:47FDA Grants Priority Review for Cabozantinib in Medullary Thyroid Cancer
05/06/12 16:11:06Cabozantinib Meets Primary Endpoint in Phase 3 Pivotal Trial in Medullary Thyroid Cancer
03/05/12 14:58:10Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration
05/03/12 16:00:21Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial
28/02/12 11:03:19Dual Inhibition of MET and VEGF Signaling With Cabozantinib Blocks Tumor Invasiveness and Metastasis
10/02/12 19:50:11Exelixis Announces Pricing of $60.5 Million Public Offering of Common Stock
03/02/12 19:14:16Cabozantinib: Encouraging Activity in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma
25/01/12 09:21:16Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular
29/11/11 00:26:48Exelixis Signs CRADA With National Cancer Institute to Expand Development Plan of Cabozantinib
21/11/11 20:06:22Exelixis Announces Initiation of Phase 2 Investigator-Sponsored Trial of Cabozantinib in Women
14/11/11 14:25:29Exelixis' Cabozantinib Phase 2 Data Demonstrate Reduction in Bone Pain
01/11/11 16:05:39Exelixis to Initiate Cabozantinib '306 Trial with Pain Endpoint in mCRPC
25/10/11 20:28:01Exelixis Appoints Executive Vice President and Chief Commercial Officer
07/09/11 16:46:40Exelixis Reaches Pre-Specified Number of Events for Final Data Analysis in EXAM Trial
05/08/11 12:49:18Exelixis Announces Second Quarter 2011 Financial Results
07/07/11 06:52:10Exelixis Provides Update on Cabozantinib Development Activities
07/06/11 10:29:21Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity
24/05/11 09:19:49Exelixis' Cabozantinib Phase 1 Clinical Trial Data published in Journal of of Clinical Oncology
04/05/11 10:56:45Exelixis Announces First Quarter 2011 Financial Results
10/03/11 16:08:43Exelixis Announces Pricing of $165.0 Million Public Offering of Common Stock
10/01/11 15:11:28Exelixis' XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
18/11/10 14:47:20Exelixis Reports Promising Interim Data from Patients with Castration-Resistant Prostate Cancer
05/11/10 11:43:31Exelixis Announces Third Quarter 2010 Financial Results
11/10/10 10:34:41Exelixis Licenses Programs to Bristol-Myers Squibb Company
06/09/10 08:28:40Exelixis Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06/08/10 08:37:59Exelixis Announces Second Quarter 2010 Financial Results
01/07/10 07:43:06Exelixis Announces Appointment of New CEO
21/06/10 09:57:55Exelixis Regains Full Rights to Develop and Commercialize XL184
07/06/10 17:20:01Exelixis Reports Updated Data from Multiple Clinical Trials of the PI3K Inhibitor XL147
07/06/10 08:26:01Exelixis Reports Updated Data from Multiple Clinical Trials of the Dual PI3K & mTOR Inhibitor XL765
03/06/10 14:56:58Exelixis to Raise $160 Million
21/05/10 08:03:30Exelixis Reports Encouraging Interim Data from an Ongoing Adaptive Randomized Discontinuation Trial
12/05/10 06:29:27Exelixis Announces First Quarter 2010 Financial Results
03/03/10 07:46:49Exelixis Announces March 9 Webcast of Its Fourth Quarter and Full Year 2009 Financial Results Confer
05/02/10 13:14:26Exelixis Announces February 9 Webcast of Presentation at the 12th Annual BioCEO

PR Manager


HR Manager


Additional Info